share_log

藥師幫:翌日披露報表

YSB: Next Day Disclosure Return

HKEX ·  Nov 26, 2024 19:39

Summary by Moomoo AI

2024年11月26日,藥師幫根據股份購買協議,發行31,678,555股新股,每股發行價12港元,作為完成對價的一部分。此次發行使得公司已發行股份總數增至675,759,001股,較之前增加4.91842%。此次股份發行已獲董事會正式授權,並遵循所有適用的上市規則和法律規定。公司確認已收取應得款項,並履行所有上市資格的先決條件。所有權文件已準備發送,相關交易已完成,並已支付購買代價。此次公告由執行董事及聯席公司秘書陳飛提交,確認所有程序均符合規定,並已在公司註冊處存檔。
2024年11月26日,藥師幫根據股份購買協議,發行31,678,555股新股,每股發行價12港元,作為完成對價的一部分。此次發行使得公司已發行股份總數增至675,759,001股,較之前增加4.91842%。此次股份發行已獲董事會正式授權,並遵循所有適用的上市規則和法律規定。公司確認已收取應得款項,並履行所有上市資格的先決條件。所有權文件已準備發送,相關交易已完成,並已支付購買代價。此次公告由執行董事及聯席公司秘書陳飛提交,確認所有程序均符合規定,並已在公司註冊處存檔。
On 26 November 2024, YSB issued 31,678,555 new shares, at an issue price of HK$12 per share, as part of the closing price. The total number of shares issued by the issuing company has increased to 675,759,001 shares, up 4.91842% previously.This share issue is duly authorized by the Board of Directors and is subject to all applicable listing rules and legal regulations. The Company confirms that the tender offer has been received and fulfils all the conditions for listing. All rights documents have been prepared for delivery, the relevant transaction has been completed, and the purchase price has been paid.This announcement has been submitted to the Executive Director and the Secretary of the Joint Undertaking, Mr Chen, to establish compliance with all procedures and has been registered with the company.
On 26 November 2024, YSB issued 31,678,555 new shares, at an issue price of HK$12 per share, as part of the closing price. The total number of shares issued by the issuing company has increased to 675,759,001 shares, up 4.91842% previously.This share issue is duly authorized by the Board of Directors and is subject to all applicable listing rules and legal regulations. The Company confirms that the tender offer has been received and fulfils all the conditions for listing. All rights documents have been prepared for delivery, the relevant transaction has been completed, and the purchase price has been paid.This announcement has been submitted to the Executive Director and the Secretary of the Joint Undertaking, Mr Chen, to establish compliance with all procedures and has been registered with the company.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more